ŽOURKOVÁ, Alexandra, Jan JUŘICA, Eva MCCASKEY HADAŠOVÁ and Lucie PULKRÁBKOVÁ. Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation. European Neuropsychopharmacology. Elsevier, 2008, vol. 18, suppl.4, p. S328-S329, 2 pp. ISSN 0924-977X. |
Other formats:
BibTeX
LaTeX
RIS
@article{777028, author = {Žourková, Alexandra and Juřica, Jan and McCaskey Hadašová, Eva and Pulkrábková, Lucie}, article_number = {suppl.4}, keywords = {disinhibition; CYP2D6; paroxetine; poor metaboliser; phenotype; genotype}, language = {eng}, issn = {0924-977X}, journal = {European Neuropsychopharmacology}, title = {Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation}, volume = {18}, year = {2008} }
TY - JOUR ID - 777028 AU - Žourková, Alexandra - Juřica, Jan - McCaskey Hadašová, Eva - Pulkrábková, Lucie PY - 2008 TI - Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation JF - European Neuropsychopharmacology VL - 18 IS - suppl.4 SP - S328-S329 EP - S328-S329 PB - Elsevier SN - 0924977X KW - disinhibition KW - CYP2D6 KW - paroxetine KW - poor metaboliser KW - phenotype KW - genotype N2 - The study unswers an important question: how long persists the inhibition after paroxetine treatment? The inhibition of CYP2D6 could exclude any substrates of CYP2D6 from the therapy. 4 weeks period seem to be sufficient for restoration of metabolic activity of CYP2D6. ER -
ŽOURKOVÁ, Alexandra, Jan JUŘICA, Eva MCCASKEY HADAŠOVÁ and Lucie PULKRÁBKOVÁ. Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation. \textit{European Neuropsychopharmacology}. Elsevier, 2008, vol.~18, suppl.4, p.~S328-S329, 2 pp. ISSN~0924-977X.
|